drugset / Trial / NCT06284876

Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

NCT06284876

Phase 3 Recruiting 416 enrolled Il-Yang Pharm. Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24

Timeline

Start
2024-07-23
Primary completion
2026-08-30
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ilaprazole Small molecule 10 mg Oral
Subject Lansoprazole Other / unclassified 15 mg Oral

Indications